Deborah Masliah Selected Research

Immunotherapy

1/2018

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deborah Masliah Research Topics

Disease

4	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2017
3	Dementia (Dementias) 01/2020 - 01/2017
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Parkinson Disease (Parkinson's Disease) 01/2018
1	Corticobasal Degeneration 01/2018
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2018
1	Tauopathies 01/2018
1	Neuroinflammatory Diseases 01/2018
1	Synucleinopathies 01/2018
1	Amyloid Plaque 01/2017

Drug/Important Bio-Agent (IBA)

3	SynucleinsIBA 01/2020 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2017
2	Amyloid (Amyloid Fibrils)IBA 01/2018 - 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2018
1	Toll-Like Receptor 2IBA 01/2018
1	Amino Acids FDA Link 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Aligeron (AS 2)IBA 01/2017

Therapy/Procedure

1	Immunotherapy 01/2018